Evidence map›Paper›PMID 38807179›Full record

ArticleBMC medicine2024

Healthy lifestyle change and all-cause and cancer mortality in the European Prospective Investigation into Cancer and Nutrition cohort.

Komodo Matta, Vivian Viallon, Edoardo Botteri, Giulia Peveri, Christina Dahm, Anne Østergaard Nannsen, Anja Olsen, Anne Tjønneland, Alexis Elbaz, Fanny Artaud and 30 more

Abstract read
In one paragraph

Article in BMC medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Triazole-(RSC advances · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Komodo MattaInternational Agency for Research on Cancer (IARC-WHO), Lyon, France.
Vivian ViallonInternational Agency for Research on Cancer (IARC-WHO), Lyon, France.
Edoardo BotteriCancer Registry of Norway (Kreftregisteret), Oslo, Norway.
Giulia PeveriDepartment of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Christina DahmDepartment of Public Health, Aarhus University, Aarhus, Denmark.
Anne Østergaard NannsenDepartment of Public Health, Aarhus University, Aarhus, Denmark.
Anja OlsenDepartment of Public Health, Aarhus University, Aarhus, Denmark.
Anne TjønnelandDanish Cancer Society Research Center, Copenhagen, Denmark.
Alexis ElbazInserm, Université Paris Saclay, Institut Gustave Roussy, Team Exposome, Heredity, Cancer and Health, CESP UMR 1018, 94807, Villejuif, France.
Fanny ArtaudInserm, Université Paris Saclay, Institut Gustave Roussy, Team Exposome, Heredity, Cancer and Health, CESP UMR 1018, 94807, Villejuif, France.
Chloé MarquesInserm, Université Paris Saclay, Institut Gustave Roussy, Team Exposome, Heredity, Cancer and Health, CESP UMR 1018, 94807, Villejuif, France.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Verena KatzkeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Matthias B SchulzeDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Erand LlanajDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Giovanna MasalaInstitute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
Valeria PalaEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Salvatore PanicoDipartimento di Medicina Clinica, Federico II University, Naples, Italy.
Rosario TuminoHyblean Association for Epidemiological Research, AIRE ONLUS, Ragusa, Italy.
Fulvio RicceriCentre for Biostatistics, Epidemiology, Department of Clinical and Biological Sciences, and Public Health (C-BEPH), University of Turin, Turin, Italy.
Jeroen W G DerksenJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Therese Haugdahl NøstK.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU - Norwegian University of Science and Technology, Trondheim, Norway.
Torkjel M SandangerDepartment of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
Kristin Benjaminsen BorchDepartment of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
J Ramón QuirósPublic Health Directorate, Asturias, Spain.
Carlota Castro-EspinInternational Agency for Research on Cancer (IARC-WHO), Lyon, France.
Maria-José SánchezEscuela Andaluza de Salud Pública (EASP), 18011, Granada, Spain.
Amaia Aizpurua AtxegaSub Directorate for Public Health and Addictions of Gipuzkoa, Ministry of Health of the Basque Government, San Sebastian, Spain.
Lluís CireraCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain.
Marcela GuevaraCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain.
Jonas ManjerDepartment of Surgery, Skåne University Hospital Malmö, Lund University, Malmö, Sweden.
Sandar Tin TinNuffield Department of Population Health (NDPH), University of Oxford, Oxford, England.
Alicia HeathSchool of Public Health, Imperial College London, London, UK.
Mathilde TouvierL'Institut national de la santé et de la recherche médicale (Inserm), Paris, France.
Marcel GoldbergUniversité Paris Descartes, Paris, France.
Elisabete WeiderpassInternational Agency for Research on Cancer (IARC-WHO), Lyon, France.
Marc J GunterInternational Agency for Research on Cancer (IARC-WHO), Lyon, France.
Heinz FreislingInternational Agency for Research on Cancer (IARC-WHO), Lyon, France.
Elio RiboliSchool of Public Health, Imperial College London, London, UK.
Pietro FerrariInternational Agency for Research on Cancer (IARC-WHO), Lyon, France. ferrarip@iarc.who.int.

Funding

Institut National du Cancer (INCa) (FR) AAP SHS-E-SP 2020Institut National du Cancer (INCa) (FR) IARC-2020-2024Institut National du Cancer (INCa) (FR) SHSESP20-071Medical Research Council MR/M012190/1World Health Organization 001
6 · The paper itself

Abstract

backgroundHealthy lifestyles are inversely associated with the risk of noncommunicable diseases, which are leading causes of death. However, few studies have used longitudinal data to assess the impact of changing lifestyle behaviours on all-cause and cancer mortality.

methodsWithin the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, lifestyle profiles of 308,497 cancer-free adults (71% female) aged 35-70 years at recruitment across nine countries were assessed with baseline and follow-up questionnaires administered on average of 7 years apart. A healthy lifestyle index (HLI), assessed at two time points, combined information on smoking status, alcohol intake, body mass index, and physical activity, and ranged from 0 to 16 units. A change score was calculated as the difference between HLI at baseline and follow-up. Associations between HLI change and all-cause and cancer mortality were modelled with Cox regression, and the impact of changing HLI on accelerating mortality rate was estimated by rate advancement periods (RAP, in years).

resultsAfter the follow-up questionnaire, participants were followed for an average of 9.9 years, with 21,696 deaths (8407 cancer deaths) documented. Compared to participants whose HLIs remained stable (within one unit), improving HLI by more than one unit was inversely associated with all-cause and cancer mortality (hazard ratio [HR]: 0.84; 95% confidence interval [CI]: 0.81, 0.88; and HR: 0.87; 95% CI: 0.82, 0.92; respectively), while worsening HLI by more than one unit was associated with an increase in mortality (all-cause mortality HR: 1.26; 95% CI: 1.20, 1.33; cancer mortality HR: 1.19; 95% CI: 1.09, 1.29). Participants who worsened HLI by more than one advanced their risk of death by 1.62 (1.44, 1.96) years, while participants who improved HLI by the same amount delayed their risk of death by 1.19 (0.65, 2.32) years, compared to those with stable HLI.

conclusionsMaking healthier lifestyle changes during adulthood was inversely associated with all-cause and cancer mortality and delayed risk of death. Conversely, making unhealthier lifestyle changes was positively associated with mortality and an accelerated risk of death.

Indexed as

Healthy LifestyleNeoplasmsAdultAgedEuropeFemaleHumansMaleMiddle AgedProspective StudiesSurveys and QuestionnairesCancerChange scoreComposite scoreHealthy lifestyle indexLongitudinalMortalityProspective study

Identifiers

PMID38807179
PMCPMC11134634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.